Is there a role for chemosensitivity tests in head and neck cancer?
Despite many advances in predictive testing of human malignancies, we are far from using it routinely in clinical practice. Investigating the responsiveness of solid tumors to cytostatic drugs is particularly challenging. Nevertheless, for head and neck cancer, chemosensitivity testing is an increasingly attractive option, since chemotherapy has proven to have curative potential in the therapy of head and neck cancer, in particular in combination with radiation. The significant need for predictive methods to identify patients responsive to therapy, first of all in organ preservation programs, which is an alternative to first-line surgery, had recently renewed the discussion on a possible role of chemosensitivity testing in head and neck cancer. In this review, we discuss the current state of chemosensitivity testing in head and neck cancer. Recent methodological developments, in particular elimination of photochemical artifacts and inclusion of stromal cell response studies, may soon augment the value of ex vivo chemosensitivity testing for the management of head and neck cancer.
Dollner
R
R
Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Operationen der Universität Leipzig, Germany.
Granzow
C
C
Werner
J A
JA
Dietz
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D010346:Patient Care Management / Q000379:methods*; D018579:Patient Selection; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods; D016896:Treatment Outcome
D000970:Antineoplastic Agents